Core Viewpoint - Xintiandi is a leading supplier of chiral pharmaceutical intermediates in China, with a full industry chain advantage and product quality meeting international standards [1] Group 1: Company Overview - Xintiandi was established on September 15, 2005, and was listed on the Shenzhen Stock Exchange on November 16, 2022, with its registered and office location in Henan Province [1] - The company primarily engages in the research, development, production, and sales of chiral pharmaceutical intermediates, operating within the pharmaceutical and biological - chemical pharmaceutical - raw materials sector [1] Group 2: Financial Performance - For Q3 2025, Xintiandi reported revenue of 481 million yuan, ranking 30th among 47 companies in the industry, while the industry leader, Prolo Pharmaceutical, achieved 7.764 billion yuan [2] - The main business composition includes L-phenylalanine series products at 300 million yuan, accounting for 83.74%, and p-toluenesulfonic acid at 52.862 million yuan, accounting for 14.78% [2] - The net profit for the same period was 91.27 million yuan, ranking 20th in the industry, with the industry leader, Zhejiang Pharmaceutical, reporting 867 million yuan [2] Group 3: Financial Ratios - As of Q3 2025, Xintiandi's debt-to-asset ratio was 12.74%, lower than the previous year's 13.12% and significantly below the industry average of 27.75%, indicating strong solvency [3] - The gross profit margin for the period was 35.86%, which, although lower than the previous year's 41.01%, remains above the industry average of 35.38% [3] Group 4: Executive Compensation - The chairman, Xie Jianzhong, received a salary of 585,400 yuan in 2024, an increase of 18,100 yuan from 2023 [4] - The general manager, Zhang Luwei, earned 488,000 yuan in 2024, up by 5,600 yuan from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 0.66% to 18,500, while the average number of circulating A-shares held per household increased by 0.66% to 5,448.09 [5]
新天地的前世今生：2025年Q3营收4.81亿行业排30，净利润9126.96万行业排20